Medical network - July 21, according to the CFDA statistics show that Chinese entities pharmacy has 447037, 2016, down 0.2% from 2015, the number of pharmacies though overall fell slightly, but the reduction, increased, there are. The reduction is closely related to the country's improvement of the entry threshold of the retail pharmacy terminal, the gradual strengthening of supervision (such as the GSP flying inspection) and the poor management of some enterprises; In terms of increasing, m Intranet found in large hospital around, quietly added several local strength strong chain stores, some forward-looking vision of retail pharmacies are visible "prescription outflow" deployment in advance; On the other hand, more chain drugstores will acquire more stores with their own development needs and capital, which will bring the 2016 chain rate (including franchisees) close to 50%.
From the number of chain enterprises in 2016, in 2016 has reached 5609 chain enterprises, a 13% increase over 2015, with the number of chain enterprises increased year by year, average each chain stores in the slide, from an average of 2010 each chain enterprises have 59 stores fell to 2016, on average, each chain only 39 stores. With the increase of chain enterprises, the ability of chain bargaining is strengthened, and the marketing cost of industry in retail channels also faces the risk of promotion.
In 2016, the sales of Chinese retail pharmacies (including pharmaceuticals and non-pharmaceuticals) were nearly 500 billion yuan
According to m Intranet data show that in 2016 China retail pharmacies (including drug and non-drug) terminal sales scale is 492.9 billion yuan, growth rate of 10.5%, among them, the entity stores (including drug and non-drug) sales scale is 464.4 billion yuan, accounting for 94.2% of the share, the growth rate of 7.6%, online pharmacies (including drug and non-drug) sales scale is 28.5 billion yuan, accounting for 5.8% of the share, the growth rate of 96.7%. In 2016, the average size of each physical drug store (including drugs and non-pharmaceutical products) reached 1039,000 yuan, up 7.9% from 2015, which is related to the consumption capacity of the population and the promotion of drug prices.
In 2016, the share of Chinese entity pharmacies increased to 72.6%
According to m Intranet data show that in 2016 China's entity of pharmacy drugs accounted for 72.6%, up 1.2% year on year, influenced by entities pharmacy reimbursement policy, the drug is still a main category of entity pharmacy, medicine class accounted for a small rise, and health care products, apparatus and instruments of all drop (see below).
In the first half of 2017, the number of drugs in China's retail pharmacies (including physical and online pharmacies) reached 181.3 billion, an increase of 8.0% year-on-year
2016 China retail pharmacies terminal (including physical and online pharmacies) drug $337.5 billion, up 8.5% from 2015, among them, the entities pharmacy drug sales scale is 332.7 billion yuan, a year-on-year growth of 8.1% in 2015; Online pharmacies and drug sales was $4.8 billion, compared with last year growth of 50.0%, but in the second half of 2016, third-party platform online drug sales, online pharmacy drug sales growth is slowing, as of the first half of 2017, China's retail pharmacy terminal (including physical and online pharmacies) medicine 181.3 billion, up 8.0% from a year earlier, among them, physical pharmacy drugs 177.8 billion, up 7.5% from a year earlier, online pharmacies and drug size 3.5 billion, up 45.8% from a year earlier.
"Non-prefecture-level cities" drug stores are growing faster than "cities and cities"
M Intranet in July 2017 launch of the "urban retail pharmacies terminal competition in China" BI data show: 2016, 2016 "above cities and city" pharmacy drug size reached 200.8 billion yuan, account for 60.35% of the scale of Chinese entities pharmacy drugs, up 7.06% from 2015; The drug size of "non-prefecture-level city" drugstores is 131.9 billion yuan, accounting for 39.65 percent, up 9.61 percent from 2015. With the improvement of China's urbanization construction, the number of county population increases, and the drug scale of "non-prefecture-level cities" will grow faster.
In 2016, the share of chemical and dual-cross varieties of Chinese urban retail pharmacies rose slightly
In retail pharmacy drug city scale in China, in 2016, the chemical medicine and double cross varieties share increased slightly, scale of chemical medicine share rose to 51.95% from 51.95% in 2015, varieties of double span size share rose from 8.6% in 2015 to 8.8%, "prescription", there are trace.
The main driving force for the growth of the chemical drug market is the use of chronic disease drugs and common diseases
In 2016, the pharmaceutical sales volume of the pharmaceutical sales of "the competition pattern of Chinese urban retail pharmacies" was about 104.4 billion yuan. From the point of scale growth, blood and hematopoietic system drugs (mainly include wave vertical dimension, tai jia, etc.), reproductive and urinary system of sex hormone drugs (mainly Mr, viagra, etc.) relatively high growth of both growth of more than 10%, the respiratory system (mainly western medicine cold, etc.), muscle, skeletal system, cardiovascular system drugs (mainly fall blood pressure, fall hematic fat, etc.) these three drugs are also more than 9.5% growth, visible elderly chronic drug use and common diseases is the main motivation of chemical medicine market growth. The impact of the country's "restrictions on resistance" also affected the retail market, with the market share falling by 0.59 percentage points, according to data from the company.
The drug of old age common disease is also the main force in the market of Chinese medicine
2016 "Chinese urban retail pharmacies terminal competition", according to the traditional size of about 96.4 billion yuan, had been ten class size growth, musculoskeletal system disease medication (mainly include hong MAO medicated wine, relaxes the muscles healthy waist pill, etc.) growth is larger, at 13.2%, followed by the respiratory system disease, growth rate of 9.84%, the two categories of drugs on the market share in 2016 also has the obvious promotion, visible geriatric diseases medicine is also the main proprietary Chinese medicine market. In the top ten proprietary Chinese medicine sub-types, gynecology medication scale appeared a negative growth, market share from 5.98% to 5.46%, mainly by the inflammation of department of gynaecology medicine, mammary gland hyperplasia drugs such as caused by the drop in sales.
|
